An RCT by Sperduto et al. revealed WBRT plus SRS in combination showed slight superior median survival, however not significant, for molecularly unselected NSCLC patients as opposed to addition of EGFR-TKIs to WBRT and SRS (13.4 vs. 6.1, p = NS) (81). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.